Saracatinib

Base Information

• Chemical Name: Saracatinib
• CAS No.: 379231-04-6
• Molecular Formula: C27H32ClN5O5
• Molecular Weight: 542.03
• UNII: 9KD24QGH76
• DSSTox Substance ID: DTXSID90191355
• Nikkaji Number: J2.424.177G
• Wikipedia: Saracatinib
• Wikidata: Q21098957
• NCI Thesaurus Code: C48378
• Pharos Ligand ID: TX69WQR41ZXD
• Metabolomics Workbench ID: 152900
• ChEMBL ID: CHEMBL217092
• Mol file: 379231-04-6.mol

Synonyms:4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1- piperazinyl)ethoxy)-5-((tetrahydro-2H-pyran-4-yl)oxy)-;AZD 0530;AZD-0530;AZD0530;AZD0530 Difumarate;N-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-((tetrahydro- 2H-pyran-4-yl)oxy)quinazolin-4-amine bi((2E)-but-2-enedioate);N-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine;saracatinib;saracatinib difumerate

Chemical Property of Saracatinib

Chemical Property:

• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.641
• Boiling Point: 671.25 °C at 760 mmHg
• PKA: 7.55±0.10(Predicted)
• Flash Point: 359.759 °C
• PSA: 90.44000
• Density: 1.349 g/cm³
• LogP: 3.88830
• Storage Temp.: -20°C
• Solubility.: Soluble in DMSO (50 mg/ml) and ethanol (54 mg/mL with warming)
• XLogP3: 4.1
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 10
• Rotatable Bond Count: 8
• Exact Mass: 541.2091968
• Heavy Atom Count: 38
• Complexity: 743

Purity/Quality:

99%min ^*data from raw suppliers

Saracatinib ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl
• Recent ClinicalTrials: AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• Recent EU Clinical Trials: Saracatinib trial TO Prevent FOP
• Description: Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases. Saracatinib is orally available and blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival. Through its effects on c-Src, it reduces osteoclast bone resorption. Saracatinib also blocks denque virus RNA replication through its effect on Fyn kinase.
• Uses: An oral, selective dual inhibitor of Src and ABL kinase. It is a COVID19-related research product. An oral, selective dual inhibitor of Src and ABL kinase.